Therapeutic Sequencing in ALK<sup>+</sup> NSCLC
Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK<sup>+</sup> NSCLC) is a model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher systemic and intracranial efficacy, the second-generation ALK tyrosine kinase inhibitors (TKI) alectinib...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/2/80 |